Crossmark

STAMP inhibitors and their future in CML therapy: a critical analysis

Crossref DOI link: https://doi.org/10.1038/s41408-025-01378-7

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yildiz, Dogan https://orcid.org/0009-0000-2210-8512
Eskazan, Ahmet Emre https://orcid.org/0000-0001-9568-0894
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 10 August 2025

Revised: 4 September 2025

Accepted: 17 September 2025

First Online: 21 October 2025

Competing interests

: The authors declare no competing interests.